An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma

BACKGROUND: Apatinib, a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, have shown remarkable efficacy in many solid cancers. But evidence of antitumor activity in patients with lymphoma is still limited. We conducted an open-label, single-arme...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ling, Xiao, Sa, Zhang, Lei, Li, Xin, Fu, Xiaorui, Wang, Xinhua, Wu, Jingjing, Sun, Zhenchang, Zhang, Xudong, Chang, Yu, Nan, Feifei, Yan, Jiaqin, Li, Zhaoming, Shi, Mengyuan, Young, Ken H., Zhang, Mingzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882329/
https://www.ncbi.nlm.nih.gov/pubmed/29662638
http://dx.doi.org/10.18632/oncotarget.23806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882329/
https://www.ncbi.nlm.nih.gov/pubmed/29662638
http://dx.doi.org/10.18632/oncotarget.23806

Ejemplares similares